Showing results (311-320 of 379) with videos related to

Sort By:
Pageof 38
Gastroenterologia Y Hepatologia|May 1, 2004
[Burden of gastroesophageal reflux disease. Evidence from a recent methodological study in Spain]J M Piqué, K R Kulich, O Vegazoc, et al.
Revista Clinica Espanola|March 11, 2006
[Psychometric validation of translation to Spanish of the gastrointestinal symptoms rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) in patients with gastroesophageal reflux disease]K R Kulich, J M Piqué, O Vegazo, et al.
Protein Engineering, Design & Selection : PEDS|June 23, 2004
Selection and characterization of HER2/neu-binding affibody ligandsM Wikman, A-C Steffen, E Gunneriusson, et al.
Pacing and Clinical Electrophysiology : PACE|January 5, 2001
Comparison of pulsed versus continuous radiofrequency energy delivery: diameter of lesions induced with multipolar ablation catheterA Erdogan, J Carlsson, H Roederich, et al.
Deutsche Medizinische Wochenschrift (1946)|October 19, 2000
[Recurrent syncope in a 34-year-old woman triathlete]J Carlsson, A Erdogan, A Rolf, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 27, 2001
Electrochemical potentials during radiofrequency energy delivery: a new method to control catheter ablation of arrhythmiasA Erdogan, J Carlsson, S Grumbrecht, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 12, 2002
[Clinical characteristics of patients with AV-nodal reentrant tachycardia (AVNRT): modification by high frequency catheter ablation. Study of 748 patients after high frequency catheter ablation]A Erdogan, B Schulte, J Carlsson, et al.
Acta Oncologica (Stockholm, Sweden)|June 25, 1999
Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetryM Lubberink, H Lundqvist, J E Westlin, et al.
Oncology Reports|March 22, 2008
In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cellsE Nordberg, A Orlova, M Friedman, et al.
Prostate Cancer and Prostatic Diseases|August 27, 2014
Prognostic significance of YWHAZ expression in localized prostate cancerK Rüenauver, R Menon, M A Svensson, et al.
Pageof 38